Skip to main content
MedWatcherBeta

Loading research and source information…

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight for Crohn’s disease: evidence and status · MedWatcher